Literature DB >> 22580166

Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.

Guilherme Baldo1, Fabiana Quoos Mayer, Barbara Martinelli, Anna Dilda, Fabiola Meyer, Katherine P Ponder, Roberto Giugliani, Ursula Matte.   

Abstract

Mucopolysaccharidosis (MPS) type I (Hurler syndrome) is a lysosomal storage disorder characterized by deficiency of alpha-L-iduronidase (IDUA), intracellular storage of glycosaminoglycans (GAGs) and progressive neurological pathology. The MPS I mouse model provides an opportunity to study the pathophysiology of this disorder and to determine the efficacy of novel therapies. Previous work has demonstrated a series of abnormalities in MPS I mice behavior, but so far some important brain functions have not been addressed. Therefore, in the present study we aimed to determine if MPS I mice have motor abnormalities, and at what age they become detectable. MPS I and normal male mice from 2 to 8 months of age were tested in open-field for locomotor activity, hindlimb gait analysis and hang wire performance. We were able to detect a progressive reduction in the crossings and rearings in the open field test and in the hang wire test in MPS I mice from 4 months, as well as a reduction in the gait length at 8 months. Histological examination of 8-month old mice cortex and cerebellum revealed storage of GAGs in Purkinje cells and neuroinflammation, evidenced by GFAP immunostaining. However TUNEL staining was negative, suggesting that death does not occur. Our findings suggest that MPS I mice have a progressive motor dysfunction, which is not caused by loss of neuron cells but might be related to a neuroinflammatory process.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580166      PMCID: PMC3390919          DOI: 10.1016/j.bbr.2012.04.051

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  26 in total

1.  Motor coordination impairment in aged heterozygous rolling Nagoya, Cav2.1 mutant mice.

Authors:  Eiki Takahashi; Kimie Niimi; Chitoshi Itakura
Journal:  Brain Res       Date:  2009-05-13       Impact factor: 3.252

2.  A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

Authors:  Monica Sifuentes; Robin Doroshow; Richard Hoft; Greg Mason; Irwin Walot; Michael Diament; Susan Okazaki; Kenneth Huff; Gerald F Cox; Stuart J Swiedler; Emil D Kakkis
Journal:  Mol Genet Metab       Date:  2006-09-29       Impact factor: 4.797

3.  Effect of cefotetan on creatinine determination by the picric acid and enzymatic methods.

Authors:  L S Mauro; V F Mauro; P C Miller; D A Lacher
Journal:  Clin Pharm       Date:  1989-07

4.  Immune and behavioral consequences of microglial reactivity in the aged brain.

Authors:  Angela M Wynne; Christopher J Henry; Jonathan P Godbout
Journal:  Integr Comp Biol       Date:  2009-04-23       Impact factor: 3.326

5.  Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI.

Authors:  Guilherme Baldo; Ursula Matte; Osvaldo Artigalas; Ida Vanessa Schwartz; Maira Graeff Burin; Erlane Ribeiro; Dafne Horovitz; Tatiana Pacheco Magalhaes; Milan Elleder; Roberto Giugliani
Journal:  Mol Genet Metab       Date:  2011-03-22       Impact factor: 4.797

Review 6.  Clinical aspects of neuropathic lysosomal storage disorders.

Authors:  Laura Bannach Jardim; Maria Mercedes Villanueva; Carolina F Moura de Souza; Cristina B Oliveira Netto
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

7.  Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

Authors:  Mayra F Garcia-Rivera; Leah E Colvin-Wanshura; Matthew S Nelson; Zhenhong Nan; Shaukat A Khan; Tyson B Rogers; Indrani Maitra; Walter C Low; Pankaj Gupta
Journal:  Brain Res Bull       Date:  2007-08-06       Impact factor: 4.077

8.  A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.

Authors:  Jason A Metcalf; Xiucui Ma; Bruce Linders; Susan Wu; Axel Schambach; Kevin K Ohlemiller; Attila Kovacs; Mark Bigg; Li He; Douglas M Tollefsen; Katherine P Ponder
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

9.  Long-term memory for aversive training is impaired in Idua(-/-) mice, a genetic model of mucopolysaccharidosis type I.

Authors:  Gustavo Kellermann Reolon; Luisa Macedo Braga; Melissa Camassola; Tatiana Luft; João Antônio Pêgas Henriques; Nance Beyer Nardi; Rafael Roesler
Journal:  Brain Res       Date:  2006-02-13       Impact factor: 3.252

10.  Murine MPS I: insights into the pathogenesis of Hurler syndrome.

Authors:  C Russell; G Hendson; G Jevon; T Matlock; J Yu; M Aklujkar; K Y Ng; L A Clarke
Journal:  Clin Genet       Date:  1998-05       Impact factor: 4.438

View more
  16 in total

1.  Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar Junior; Vânia D'Almeida
Journal:  J Mol Histol       Date:  2020-03-11       Impact factor: 2.611

2.  Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.

Authors:  Li Ou; Michael J Przybilla; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-10-11       Impact factor: 4.797

3.  Morphological damage in Sertoli, myoid and interstitial cells in a mouse model of mucopolysaccharidosis type I (MPS I).

Authors:  Cinthia Castro do Nascimento; Odair Aguiar; Gustavo Monteiro Viana; Vânia D'Almeida
Journal:  Mol Biol Rep       Date:  2020-12-15       Impact factor: 2.316

4.  Enhancement of neuromuscular dynamics and strength behavior using extremely low magnitude mechanical signals in mice.

Authors:  Gabriel Mettlach; Luis Polo-Parada; Lauren Peca; Clinton T Rubin; Florian Plattner; James A Bibb
Journal:  J Biomech       Date:  2013-10-09       Impact factor: 2.712

5.  Altered Cellular Homeostasis in Murine MPS I Fibroblasts: Evidence of Cell-Specific Physiopathology.

Authors:  Gustavo Monteiro Viana; Cinthia Castro do Nascimento; Edgar Julian Paredes-Gamero; Vânia D'Almeida
Journal:  JIMD Rep       Date:  2017-02-21

6.  Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.

Authors:  Roselena Silvestri Schuh; Esteban Alberto Gonzalez; Angela Maria Vicente Tavares; Bruna Gazzi Seolin; Lais de Souza Elias; Luisa Natalia Pimentel Vera; Francyne Kubaski; Edina Poletto; Roberto Giugliani; Helder Ferreira Teixeira; Ursula Matte; Guilherme Baldo
Journal:  Gene Ther       Date:  2019-12-11       Impact factor: 5.250

7.  Characterization of joint disease in mucopolysaccharidosis type I mice.

Authors:  Patricia G de Oliveira; Guilherme Baldo; Fabiana Q Mayer; Barbara Martinelli; Luise Meurer; Roberto Giugliani; Ursula Matte; Ricardo M Xavier
Journal:  Int J Exp Pathol       Date:  2013-06-21       Impact factor: 1.925

8.  Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice.

Authors:  A S Azambuja; L N Pimentel-Vera; E A Gonzalez; E Poletto; C V Pinheiro; U Matte; R Giugliani; Guilherme Baldo
Journal:  Metab Brain Dis       Date:  2020-07-04       Impact factor: 3.584

9.  Effects of enzyme replacement therapy started late in a murine model of mucopolysaccharidosis type I.

Authors:  Gabriela Pasqualim; Guilherme Baldo; Talita Giacomet de Carvalho; Angela Maria Vicente Tavares; Roberto Giugliani; Ursula Matte
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

10.  Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).

Authors:  Paola Saccone; Gabriella Cotugno; Fabio Russo; Rosa Mastrogiacomo; Alessandra Tessitore; Alberto Auricchio; Elvira De Leonibus
Journal:  Sci Rep       Date:  2014-01-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.